This committee will not stop until our questions are answered and any appropriate actions are taken.” Mylan has come under fire for raising the price of a pair of EpiPens to $600 from $100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U.S. Food and Drug Administration as a branded product.